Cognition Therapeutics Receives Nasdaq Minimum-Bid Deficiency Notice, Has Until May 3, 2027 to Cure
CGTX sits 24% above its 52-week low of $0.55.
Summary
Cognition Therapeutics received a Nasdaq notice that its stock has traded below $1.00 for 30 business days, giving it until May 3, 2027 to regain compliance, likely via a reverse split. Q3 results showed a narrower $4.1M loss and cash runway into Q4 2027.
Key Events · Legal and Risk Events · CGTX
-
Nasdaq Minimum-Bid Deficiency Notice
On November 3, 2026, Nasdaq notified the company that its closing bid price had been below the $1.00 minimum under Rule 5450(a)(1) for the last 30 consecutive business days. The stock continues to trade on the Nasdaq Capital Market under CGTX in the meantime.
-
Cure Deadline May 3, 2027
The company has 180 calendar days, until May 3, 2027, to close at $1.00 or more for at least 10 consecutive business days. Failing that, a second 180-day period is possible only if the company notifies Nasdaq of its intent to cure, by effecting a reverse stock split if necessary.
-
Q3 Loss Narrows to $4.1M
Net loss for the quarter ended September 30, 2026 was $4.1M, or $(0.04) per share, versus $4.9M, or $(0.06), a year earlier. R&D rose to $5.1M from $3.8M on higher CRO trial activity, while G&A fell to $2.3M from $2.6M.
-
Cash Runway Into Q4 2027
Cash, cash equivalents and restricted cash equivalents were $31.5M at September 30, 2026, down from $37.0M at December 31, 2025, with $18.2M of obligated National Institute on Aging grant funds remaining. Management estimates funding through Q4 2027.
Analysis · CGTX · Life Sciences
Nasdaq has formally put Cognition on notice after the stock closed below $1.00 for 30 straight business days. Nothing changes today — CGTX keeps trading — but the clock now runs to May 3, 2027, and the most likely fix is a reverse stock split, which would shrink the share count without changing the value of anyone's stake. The Q3 numbers underneath are steady rather than alarming: the loss narrowed to $4.1M from $4.9M, and $31.5M of cash plus $18.2M of remaining grant money carries the company into Q4 2027. The real tension is that the planned Phase 3 DLB trial is the value driver, and a sub-$1 stock makes raising the money for it harder and more dilutive.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGTX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65M. The 52-week trading range was $0.55 to $1.83. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.